Merger activity sizzles in the food business, Apple experiments with Beats, and Pfizer stays disciplined.
New hit products could provide some upside for Apple but aren't needed to support the current valuation, says Morningstar's Brian Colello.
Apple's gross margins likely will shrink over time, but the market is underestimating the long-term potential of the iPhone, says Morningstar's Brian Colello.
Solid iPhone sales and aggressive share repurchases outweighed iPad weakness and a China slowdown in Apple's fiscal third quarter, says Morningstar's Brian Colello.
©2014 Morningstar Advisor. All right reserved.